The Chemours Company Reports Fourth Quarter and Full Year 2025 Results: What Investors Need to Know

Wilmington, Del., February 19, 2026 – The Chemours Company (NYSE: CC), a global leader in industrial and specialty chemicals, has released its financial results for the fourth quarter and full year ended December 31, 2025. The results contain significant developments that current and prospective investors should closely consider.

Key Highlights from Q4 and Full Year 2025

• Q4 2025 Net Sales: \$1.329 billion, down 2% from Q4 2024 (\$1.359 billion) and down 11% sequentially from Q3 2025 (\$1.495 billion). Full year net sales were \$5.808 billion, essentially flat versus 2024.
• Net Loss: Q4 2025 net loss attributable to Chemours was \$47 million (or \$0.31 per diluted share), compared to a net loss of \$11 million (or \$0.08 per diluted share) in Q4 2024. For the full year 2025, net loss was \$386 million, a steep decline from net income of \$69 million in 2024.
• Adjusted Net Income (Non-GAAP): Q4 2025 adjusted net income was \$7 million (or \$0.05 per diluted share), compared to \$14 million (or \$0.09 per diluted share) in Q4 2024. For the year, adjusted net income was \$143 million, down from \$179 million in 2024.
• Adjusted EBITDA: Q4 2025 adjusted EBITDA was \$128 million, down 24% year-over-year. Full year adjusted EBITDA was \$742 million, down from \$768 million in 2024.
• Adjusted EPS: Q4 2025 adjusted EPS was \$0.05, down from \$0.09 in Q4 2024. Full year adjusted EPS was \$0.95, down from \$1.19 in 2024.
• Record Performance in Opteon Refrigerants: The Thermal & Specialized Solutions (TSS) business posted a record fourth quarter, with 37% year-over-year growth in its Opteon refrigerants line.

Segment Performance and Strategic Initiatives

Thermal & Specialized Solutions (TSS)

• Strong Growth: Q4 2025 net sales surged 14% year-over-year to \$444 million, mainly driven by double-digit growth in Opteon refrigerants.
• Adjusted EBITDA: \$128 million for Q4, up from \$113 million in Q4 2024. Full year adjusted EBITDA was \$545 million, up 17% year-over-year.

Titanium Technologies (TT)

• Sales Decline: Q4 2025 net sales dropped 11% year-over-year to \$561 million, reflecting challenging global TiO₂ demand and lower pricing.
• Adjusted EBITDA: \$23 million, a steep 67% year-over-year drop due to unfavorable product mix, lower volumes, and a sizable non-cash inventory charge.
• Strategic Update: Chemours announced the sale of its Kuan Yin TiO₂ site, which will provide significant cash inflow in 2026 and support ongoing debt reduction efforts.

Advanced Performance Materials (APM)

• Sales Weakness: Q4 2025 net sales were flat sequentially but declined 5% year-over-year to \$1.3 billion for the full year, reflecting weaker global demand across cyclical end markets.
• Adjusted EBITDA: Q4 2025 adjusted EBITDA was \$12 million (down 74% year-over-year), while full year adjusted EBITDA was \$108 million (down 32%). Lower cost absorption tied to reduced production and operational disruptions impacted results.
• Operational Actions: Closure of a production line and actions to reduce inventory and promote cash flow.

Other Segments and Corporate Expenses

• Performance Chemicals and Intermediates: Q4 2025 net sales were \$12 million with \$1 million in adjusted EBITDA. Full year sales were \$51 million and adjusted EBITDA was \$8 million.
• Corporate Expenses: \$33 million in Q4 2025, a reduction of \$36 million from the prior year, mainly due to lower litigation costs and cost-cutting initiatives under the “Pathway to Thrive” strategy.

Liquidity, Debt, and Capital Allocation

• Cash and Cash Equivalents: Ended 2025 at \$670 million, down from \$713 million a year earlier.
• Capital Expenditures: For 2026, expected to be \$275–\$325 million.
• Debt Reduction Focus: Proceeds from the Kuan Yin TiO₂ site sale and improved organic cash flow are expected to meaningfully reduce net leverage, with a target of maintaining net leverage below 3x Adjusted EBITDA across economic cycles.
• Free Cash Flow Conversion: Expected to be above 25% in 2026, supported by earnings and working capital improvements.
• Dividend Payments: \$78 million paid out in 2025, reduced from \$148 million in 2024.

Guidance and Outlook for 2026

• Estimated Adjusted EBITDA: \$800 million to \$900 million for 2026, a notable improvement from 2025 (\$742 million).
• Estimated Adjusted Net Income: \$130 million to \$180 million, reversing the 2025 GAAP net loss of \$386 million.
• Free Cash Flows: Projected between \$200 million and \$270 million for 2026.

Non-GAAP Measures and Restatements

• Restatements: Certain prior period amounts have been revised to correct for immaterial errors.
• Non-GAAP Metrics: The company emphasizes Adjusted Net Income, Adjusted EBITDA, and Free Cash Flows as key management and investor metrics, noting they exclude certain litigation and environmental costs, among others.
• Net Leverage Ratio: As of year-end, the non-GAAP net leverage ratio stood at 4.7x, versus 4.5x in the prior year.

Litigation and Environmental Matters

• Ongoing Legal Risks: Litigation related to legacy environmental matters, including PFAS liabilities, remains a risk factor. The company continues to incur and settle litigation expenses, which impact both GAAP and non-GAAP results.
• Restricted Cash: At year-end, \$54 million in restricted cash, mainly escrow payments related to memoranda of understanding (MOU) with DuPont, Corteva, and EID.

Forward-Looking Risks

• Forward-looking statements are subject to risks, including economic and geopolitical uncertainties, regulatory changes, environmental liabilities, supply chain disruptions, and ongoing litigation.
• Investors are cautioned that forward-looking guidance does not guarantee future results and is subject to change based on market and operational developments.

Key Takeaways for Investors

• Significant Full-Year Loss: The reported GAAP net loss of \$386 million for 2025 is a sharp reversal from the previous year’s profit, due in part to non-cash charges, weaker demand in key segments, and ongoing legal and restructuring costs.
• Deleveraging Actions: Sale of assets and focus on cash generation are expected to reduce leverage and support the balance sheet.
• Operational and Strategic Adjustments: Cost reduction, restructuring, and selective asset sales are in focus to improve profitability and cash flow.
• Improved Outlook for 2026: Despite these challenges, management projects a return to profitability and stronger cash flows in 2026, assuming macroeconomic stabilization and execution of planned initiatives.
• Litigation and Environmental Exposure: Ongoing legal matters and environmental liabilities remain a material risk for the company and its shareholders.

Conference Call Details

Chemours will host a conference call and webcast on February 20, 2026, at 8:00 AM Eastern Time. Materials and replay will be available on the company’s investor website.

Contact Information

Investors: Brandon Ontjes, VP, Head of Strategy & Investor Relations, +1.302.773.3309, [email protected]
Media: Cassie Olszewski, Media Relations & Reputation Leader, +1.302.219.7140, [email protected]

Disclaimer: This article summarizes financial results and forward-looking statements from The Chemours Company’s official filings. It is not investment advice. Actual results may differ materially due to risks and uncertainties. Investors should review Chemours’ SEC filings and consult with financial advisors before making investment decisions.

View Chemours Co Historical chart here